NASDAQ:MIRA MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis $1.55 -0.03 (-1.90%) (As of 09/6/2024 08:49 PM ET) Add Compare Share Share Today's Range$1.54▼$1.6350-Day Range$0.54▼$5.0152-Week Range$0.51▼$6.48Volume212,800 shsAverage Volume2.35 million shsMarket Capitalization$22.91 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get MIRA Pharmaceuticals alerts: Email Address MIRA Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside609.7% Upside$11.00 Price TargetShort InterestHealthy3.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.60) to ($0.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.13 out of 5 starsMedical Sector520th out of 909 stocksPharmaceutical Preparations Industry237th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingMIRA Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMIRA Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about MIRA Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.91% of the float of MIRA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMIRA Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MIRA Pharmaceuticals has recently decreased by 16.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMIRA Pharmaceuticals does not currently pay a dividend.Dividend GrowthMIRA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MIRA. Previous Next 1.4 News and Social Media Coverage News SentimentMIRA Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MIRA Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for MIRA on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added MIRA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MIRA Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 35.16% of the stock of MIRA Pharmaceuticals is held by institutions.Read more about MIRA Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MIRA Pharmaceuticals are expected to grow in the coming year, from ($0.60) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MIRA Pharmaceuticals is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MIRA Pharmaceuticals is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMIRA Pharmaceuticals has a P/B Ratio of 10.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MIRA Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Mode MobilePre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.Claim Exclusive 100% Bonus: $0.25/Share About MIRA Pharmaceuticals Stock (NASDAQ:MIRA)MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Read More MIRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIRA Stock News HeadlinesSeptember 4, 2024 | msn.comBioMedNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific AdvisorAugust 31, 2024 | americanbankingnews.comMIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Sees Large Decrease in Short InterestSeptember 9, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.August 27, 2024 | msn.comMIRA Announces Significant Test ResultsAugust 26, 2024 | msn.comMidday stock movers: Temu Parent, Planet Fitness, MIRA PharmaceuticalsAugust 26, 2024 | benzinga.comMIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal StudiesAugust 26, 2024 | msn.comWhy MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving PremarketAugust 24, 2024 | marketwatch.comStocks to Watch: MIRA Pharmaceuticals, Talis BiomedicalSeptember 9, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.August 24, 2024 | marketwatch.comMIRA Pharmaceuticals' Shares Soar on Ketamine-Analog Drug Study ResultsAugust 24, 2024 | markets.businessinsider.comMIRA Reports Promising Pre-Clinical Results For Ketamir-2 In Neuropathic Pain Study; Stock UpAugust 18, 2024 | finance.yahoo.comMIRA Pharmaceuticals, Inc. (K6S.F)August 16, 2024 | msn.comMIRA Continues to Reveal Advances in TreatmentAugust 14, 2024 | finance.yahoo.comIntelliguard, Cencora Partner to Increase Compatibility of RFID-Tagged Medications, Medication Management SystemsAugust 13, 2024 | finanznachrichten.deTELOMIR PHARMACEUTICALS, INC.: Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher ChapmanAugust 13, 2024 | msn.comMIRA Mira Pharmaceuticals files $100M mixed securities shelfAugust 12, 2024 | finance.yahoo.comTelomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher ChapmanAugust 12, 2024 | marketwatch.comTelomir Pharmaceuticals Chair, CEO Christopher Chapman Passes AwaySee More Headlines Receive MIRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MIRA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/08/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MIRA Previous SymbolNASDAQ:MIRA CUSIPN/A CIK1904286 Webmirapharmaceuticals.com Phone737-289-0835FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+609.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-286.24% Return on Assets-246.14% Debt Debt-to-Equity RatioN/A Current Ratio3.68 Quick Ratio3.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book10.33Miscellaneous Outstanding Shares14,781,000Free FloatN/AMarket Cap$22.91 million OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Erez Aminov (Age 45)CEO & Chairman Comp: $337.05kMs. Michelle Yanez M.B.A. (Age 51)CFO, Secretary & Treasurer Comp: $338.77kDr. Itzchak Angel Ph.D.Chief Scientific AdvisorKey CompetitorsAssertioNASDAQ:ASRTMetagenomiNASDAQ:MGXCervoMedNASDAQ:CRVOAdlai NortyeNASDAQ:ANLPyroGenesis CanadaNASDAQ:PYRGFView All CompetitorsInsidersErez AminovBought 8,700 shares on 5/21/2024Total: $8,178.00 ($0.94/share)Brian Patrick McnultySold 46,005 sharesTotal: $71,307.75 ($1.55/share)Brian Patrick McnultySold 19,053 sharesTotal: $30,675.33 ($1.61/share)Brian Patrick McnultySold 27,733 sharesTotal: $81,812.35 ($2.95/share)Brian Patrick McnultySold 61,331 sharesTotal: $244,097.38 ($3.98/share)View All Insider Transactions MIRA Stock Analysis - Frequently Asked Questions How have MIRA shares performed this year? MIRA Pharmaceuticals' stock was trading at $1.05 on January 1st, 2024. Since then, MIRA shares have increased by 47.6% and is now trading at $1.55. View the best growth stocks for 2024 here. How were MIRA Pharmaceuticals' earnings last quarter? MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) announced its earnings results on Tuesday, August, 13th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.01. When did MIRA Pharmaceuticals IPO? MIRA Pharmaceuticals (MIRA) raised $9 million in an initial public offering (IPO) on Thursday, August 3rd 2023. The company issued 1,275,000 shares at $7.00 per share. How do I buy shares of MIRA Pharmaceuticals? Shares of MIRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MIRA) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredForget polls, focus on these 5 tickersWith all the geopolitical tensions in the world… all the inflation… all the expectations of a new round of Fed...StockEarnings | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.